Pharmacokinetic analysis of the FDA guidance for industry - 'Topical dermatologic corticosteroids: In vivo bioequivalence'

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 56, Issue 1, 2003, Pages 53-58

  Leopold, Claudia S ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Bioavailability; Bioequivalence; Corticosteroids; FDA; Pharmacokinetics; Skin blanching

Indexed keywords

CORTICOSTEROID DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALCULATION; DRUG FORMULATION; DRUG INDUSTRY; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; IN VIVO STUDY; KINETICS; MEDICAL ASSESSMENT;

EID: 0038015547     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(03)00045-6     Document Type: Article

References (28)

1. Shah V.P., Flynn G.L., Yacobi A., Maibach H.I., Bon C., Fleischer N.M., Franz T.J., Kaplan S.A., Kawamoto J., Lesko L.J., Marty J.P., Pershing L.K., Schaefer H., Sequeira J.A., Shrivastava S.P., Wilkin J., Williams R.L. Bioequivalence of topical dermatological dosage forms - methods of evaluation of bioequivalence. Pharm. Res. 15:1998;167-171.
2. FDA, Topical dermatologic corticosteroids: in vivo bioequivalence, Guidance for Industry, 1995.
3. McKenzie A.W., Stoughton R.B. Method for comparing percutaneous absorption of steroids. Arch. Dermatol. 86:1962;608-610.
4. Haleblian J.K. Bioassays used in development of topical dosage forms. J. Pharm. Sci. 65:1976;1417-1436.
5. Haigh J.M.K.I. Assessment of topical corticosteroid preparations: the human skin blanching assay. Int. J. Pharm. 19:1984;245-262.
6. Shah V.P., Elkins J., Skelly J.P. Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams. J. Pharm. Sci. 81:1992;104-106.
7. Pershing L.K., Silver B.S., Krueger G.G., Shah V.P., Skelley J.P. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharm. Res. 9:1992;45-51.
8. Pershing L.K. New approaches to assess topical corticosteroid bioequivalence - pharmacokinetic evaluation. Int. J. Dermatol. 31:1992;14-20.
9. Conner D.P., Zamani K., Almirez R.G., Millora E., Nix D., Shah V.P. Use of reflectance spectrophotometry in the human corticosteroid skin blanching assay. J. Clin. Pharmacol. 33:1993;707-711.
10. Andersen P., Milioni K., Maibach H. The cutaneous corticosteroid vasoconstriction assay: a reflectance spectroscopic and laser-Doppler flowmetric study. Br. J. Dermatol. 128:1993;660-665.
11. Noon J.P., Evans C.E., Haynes W.G., Webb D.J., Walker B.R. A comparison of techniques to assess skin blanching following the topical application of glucocorticoids. Br. J. Dermatol. 134:1996;837-842.
12. Montenegro L., Ademola J.I., Bonina F.P., Maibach H.I. Effect of application time of betamethasone-17-valerate 0.1% cream on skin blanching and stratum corneum drug concentration. Int. J. Pharm. 140:1996;51-60.
13. Demana P.H., Smith E.W., Walker R.B., Haigh J.M., Kanfer I. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. Pharm. Res. 14:1997;303-307.
14. Schwarb F.P., Smith E.W., Haigh J.M., Surber C. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data. Eur. J. Pharm. Biopharm. 47:1999;261-267.
15. Singh G.J.P., Adams W.P., Lesko L.J., Shah V.P., Molzon J.A., Williams R.L., Pershing L.K. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin. Pharmacol. Ther. 66:1999;346-357.
16. Pershing L.K., Lambert L.D., Shah V.P., Lam S.Y. Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05-percent betamethasone dipropionate bioavailability in humans. Int. J. Pharm. 86:1992;201-210.
17. Leopold C.S. How accurate is the determination of the relative bioavailability of transdermal drug formulations from pharmacodynamic response data? Pharm. Acta Helv. 73:1998;63-67.
18. Leopold C.S. The maximum pharmacodynamic effect as a response parameter: pharmacokinetic considerations. J. Pharm. Pharmacol. 51:1999;999-1008.
19. Leopold C.S., Maibach H.I. Percutaneous penetration of local anesthetic bases: pharmacodynamic measurements. J. Invest. Dermatol. 113:1999;101-104.
20. Leopold C.S. The effect of cream and ointment bases on the steady state penetration of permeants through intact skin: the reciprocal of the onset time of a pharmacodynamic effect as parameter of response. Int. J. Cosmet. Sci. 22:2000;133-145.
21. Lippold B.C., Reimann H. Wirkungsbeeinflussung bei Lösungssalben durch Vehikel am Beispiel von Methylnicotinat, Teil II: Beziehung zwischen relativer thermodynamischer Aktivität und Bioverfügbarkeit: Penetrationsbeschleunigung und Entleerungseffekt. Acta Pharm. Technol. 35:1989;136-142.
22. Bach M., Lippold B.C. Influence of penetration enhancers on the blanching intensity of betamethasone 17-benzoate. Int. J. Pharm. 168:1998;97-108.
23. Leopold C.S. Quantification of depletion in solution-type topical preparations in vivo. J. Cosmet. Sci. 49:1998;165-174.
24. Lippold B.C., Schneemann H. The influence of vehicle on the local bioavailability of betamethason-17-benzoate from solution- and suspension-type ointments. Int. J. Pharm. 22:1984;31-43.
25. Singh G.J.P., Lesko L.J., Shah V.P., Wilkin J., Williams R.L. Evaluation of the FDA pilot dose-response study for topical dermatologic corticosteroids. Pharm. Res. 14:1997;S320.
26. Singh G.J.P., Lesko L.J., Shah V.P., Wilkin J., Williams R.L. Evaluation of the in vivo bioequivalence study recommended by FDA for multisource topical dermatologic corticosteroids. Pharm. Res. 14:1997;S320.
27. Leopold C.S., Lippold B.C. Enhancing effects of lipophilic vehicles on skin penetration of methyl nicotinate in vivo. J. Pharm. Sci. 84:1995;195-198.
28. Leopold C.S., Lippold B.C. Enhancer effects of lipophilic vehicles on skin penetration of methyl nicotinate in vivo. Proc. Int. Symp. Controlled Release Bioact. Mater. 20:1993;16-17.